Therapy of metastatic urothelial cancer

Abstract

The gold standard for the therapy of metastatic or inoperable urothelial cancer is the combination of gemcitabine and cisplatin as first-line treatment and immunotherapy with pembrolizumab, atezolizmab or nivolumab as second-line treatment. For patients who are not eligible for standard cisplatin-containing chemotherapy, pembrolizumab and atezolizumab are first-line treatment options. In the future, targeted therapies and immunotherapeutics, e.g., in maintenance therapy, will influence the therapeutic landscape of advanced urothelial carcinoma.